CD19-targeted BiTE expression by an oncolytic vaccinia virus significantly augments therapeutic efficacy against B-cell lymphoma

Wen Lei¹², Qian Ye¹,², Yuanyuan Hao¹,², Jie Chen³, Yu Huang⁴, Liu Yang⁵, Shibing Wang⁶ and Wenbin Qian¹²

© The Author(s) 2022

Immunotherapy with CD19-targeting bispecific T-cell engagers (CD19BiTEs) has demonstrated highly effective killing of cancer cells in patients with precursor acute lymphoblastic leukemia and non-Hodgkin’s lymphomas. However, there are some drawbacks to this therapy, such as toxicity, short half-life in the serum, and immunosuppressive tumor microenvironment that could limit the use of CD19BiTEs in the clinic. Here, we generate an oncolytic vaccinia virus (OVV) encoding a CD19-specific BiTE (OVV-CD19BiTE). We demonstrate that OVV-CD19BiTE’s ability to replicate and induce oncolysis was similar to that of its parental counterpart. Supernatants from OVV-CD19BiTE-infected cells could induce activation and proliferation of human T cells, and the bystander effect of the virus was also demonstrated. In vivo study showed that OVV-CD19BiTE selectively replicated within tumor tissue, and contributed to a more significantly increased percentage of CD3, CD8, and naive CD8 T subpopulations within tumors in contrast to blinatumomab. More importantly, treatment with OVV-CD19BiTE both in vitro and in vivo resulted in potent antitumor activity in comparison with control OVV or blinatumomab, a first-in-class BiTE, thereby resulting in long-term tumor remissions without relapse. The study provides strong evidence for the therapeutic benefits of CD19-targeting BiTE expression by OVV, and suggests the feasibility of testing the approach in clinical trials.

Blood Cancer Journal (2022) 12:35; https://doi.org/10.1038/s41408-022-00634-4

INTRODUCTION

With the major progress made in recent years, CD19-based immunotherapy has changed the treatment pattern of relapsed or refractory (R/R) B-cell malignancies [1, 2]. Bispecific T-cell engagers (BiTEs) are novel immunotherapeutic molecules that consist of an anti-CD3 single-chain variable fragment (scFv) fused to the scFv targeting antitumor-associated antigen via a flexible linker. BiTE-mediated T-cell-antigen-positive target cell crosslink triggers the formation of cytolytic synapses, which results in tumor-specific cell lysis, and can overcome elements of tumor-associated immunosuppression that limit physiologic immune responses, leading to reactivation and proliferation of exhausted tumor-specific T cells [3, 4]. Blinatumomab, a CD19/CD3 BiTE, has been approved in the R/R B-cell precursor acute lymphoblastic leukemia (ALL) based on the Phase III TOWER study that demonstrated improved overall survival (OS) and complete remission (CR) when compared to standard of chemotherapy [5, 6]. It has also shown promise for use in non-Hodgkin lymphoma (NHL) [7]. However, NHL patients with extramedullary involvement may be more resistant to BiTE therapy [8], suggesting a limited capacity of BiTEs to penetrate the tumors. Other limitations are that the short half-life of blinatumomab requires a continuous infusion over 6–8 weeks which is the major hurdle of use in the clinic [6, 7], and the majority of patients receiving this drug had grade 3 or higher adverse events (AEs) [5].

To enhance the efficacy of BiTE agents and decrease unwanted AEs due to systemic administration, local delivery of BiTEs at the tumor site would provide consistent, durable therapeutic responses against cancers without systemic toxicity. Oncolytic viruses (OVs) selectively infect, replicate in, and destroy tumor cells, representing a new class of therapeutic agents. Clinical trials have demonstrated the safety and potential of OVs [9]. Moreover, it has been well known that OVs also induce antitumor immune responses and revert immune suppression, which functions to eradicate cancer cells within the tumor microenvironment (TME) [3, 10, 11]. We and others have previously demonstrated that OVs can be “armed” to express therapeutic transgenes, and secrete them from infected cancer cells, thereby significantly enhancing its antitumor activity [12–15]. Additionally, several novel OVs armed with BiTE, such as EGFR, EphA2, and FAP, have been shown to enhance T-cell activation and proliferation, increase the persistence and accumulation of T cells in tumors, and result in higher antitumor efficacy compared to the parental virus [16–19].
Among OVs, vaccinia virus possesses many positive attributes that make them a more attractive platform for genetically modified OV-based immunotherapy. Vaccinia viruses have a large genome with the capacity for arming multiple therapeutic genes and replicating in the cytoplasm, therefore, minimizing any chance of integration into the host genome [15]. It has a long track record of safety when used as a smallpox vaccine [20]. More importantly, intravenous delivery of oncolytic vaccinia virus (OVV) in cancer patients showed persistent infection in metastatic tumors and induction of anticancer immune responses [21, 22].

In this study, we generated an OVV encoding bispecific T-cell engagers (OVV-CD19BiTE) that bound both to human CD3 and a lymphoma cell surface antigen CD19 and assessed its efficacy in vitro and in vivo. Furthermore, we investigated the possible mechanisms of efficacy with attention to T-cell recruitment, activation, and differentiation.

**METHODS**

**Cell lines and cell culture**

The cell lines used in this study included Raji (Human Burkitt’s lymphoma cell), Farage (Human B-cell lymphoma cell), Pfeifer (Diffuse large B-cell lymphoma cell), Nalm-6 (Human B-cell lymphocyte leukemia cell), Jurkat (Human T-cell lymphocyte leukemia cell), CEM (Human T-cell lymphocyte leukemia cell), HEK293 (human embryonic kidney cell), and Hela-S3 (Human cervix carcinoma cell), K562 (Human chronic myelogenous leukemia cell), and K562/CD19 (K562 cells transfected with human CD19 antigen). HEK293 and Hela-S3 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Cat#: 11960092, Gibco-Thermo Fisher Scientific, USA) supplemented with 10% fetal bovine serum (FBS; Cat#:16000044, Gibco). Raji, Farage, Pfeifer, Nalm-6, Jurkat, CEM, K562, and K562/CD19 cells were cultured in RPMI 1640 medium (Cat#: 11875093, Gibco) supplemented with 10% FBS (Cat#:16000044, Gibco). Hela-S3 cells were cultured in suspension in a serum-free medium (Cat#: H740KJ, Basalmedia, Shanghai, China) in spinner flasks (Cat#: TC8002002, Jetbiofl, Guangzhou, China). All cells were incubated at 37 °C with 5% CO2 atmosphere.

**Recombinant OVV construction, purification, and expansion**

The shuttle plasmid pRGB001 was synthesized by GenScript (Nanjing, China). In this plasmid, the reporter gene EGFP and the screening gene guanine-hypoxanthine phosphoribosyl transferase (GPT) are linked by a T2A peptide sequence and are under the control of the p-7.5k early/later guanine-hypoxanthine phosphoribosyl transferase (GPT) are linked by a T2A peptide sequence and are under the control of the p-7.5k promoter to control the expression of foreign genes. These chimeric genes are flanked by the left (TKL) and right (TKR) fragments of the VV thymidine kinase (TK) gene. CD19-targeted BiTE was constructed by linking a scFv recognizing human CD19 (clone FMC63) to a scFv recognizing human CD3ε (clone OKT3) via a flexible glycy-serine-lyser (G4S) linker. The anti-CD19 and anti-CD3 variable regions were connected by a (G4S)3 and a (G2S)4GG linkers, respectively. The CD19BiTE was arranged VHCID19-VLCD19-VHCD33-VLCD3 and included the signal peptide (SP) from the mouse Ig heavy chain and a FLAG tag at the N- and C-terminus of the protein, respectively. Finally, the CD19BiTE construct was optimized for human codon usage and synthesized by Genscript and subclone into the pRGB001 plasmid to construct a recombinant shuttle plasmid (pRGB001-CD19BiTE) for expressing the CD19BiTE under the control of the p-se/l promoter.

To generate recombinant OVV, a Western Reserve (WR) strain (ATCC VR-1354) was used as a parental virus for homologous recombination. In brief, HEK293 cells were infected with WR at a multiplicity of infection (MOI) of 0.1 for 4 h and then transfected with the corresponding shuttle plasmid using Lipofectamine 3000 transfection reagent (Cat#: L3000015, Thermo-Fisher, USA). The cell extraction solution was used to infect the HEK293 cells in the presence of 25 mg/ml mycophenolic acid (MPA; Cat#: A600640, Sangon Biotech, Shanghai, China), 250 mg/ml xanthine (Cat#: A601197, Sangon Biotech), and 15 mg/ml hypoxanthine (Cat#: A500336, Sangon Biotech). After three cycles of screening, EGFP-positive plaques were isolated, resuspended, and further infected HEK293 cells for two cycles of plaque purification. After completing the first and second rounds of plaque purification, the following primers were used to amplify the target gene and the viral TK gene to identify whether the recombinant virus was adulterated with the parental vaccinia virus. Primer of target gene: 5'-GGCAACCCCAACAGGGATG-3', 5'-CGGAGCTCGTCTGTTGTCG-3'; Primer of TK: 5'-TGTAAGAGCTAGAAAAATATTGATC-3', 5'-GTTGGCCATACGGCTACAG-3'. Recombinant vaccinia virus successfully screened by plaque purification was further expanded by Hela-S3 cells in six-well plates, cell culture dishes, and cell culture spinner flasks.

**Replication of the oncolytic vaccinia virus in lymphoma cells**

Tumor cells (Raji, Farage, and K562/CD19) were seeded in a 24-well plate at 6 × 105 cells per well and placed in a 5% CO2 incubator at 37 °C, and then infected with recombinant OVVs at MOIs of 0.5. The cells were harvested after 24, 48, 72, and 96 h and then disrupted by three freeze-thaw cycles, and centrifuged at 1000 × g for 30 min. The virus supernatants were collected and the virus titer was determined by an TCID50 method.

**CCK8 assay**

For the CCK8 assay, Raji, Farage, Pfeifer, and K562/CD19 cells were seeded in a 96-well plate at 8 × 103 cells per well and then infected with OVV at indicated MOIs in triplicate. After 72 h incubation, 20 μl of CCK8 solution (Cat#: C0037; Beyotime, Shanghai, China) was added to each well of the plate and incubated for 4 h. The absorbance was measured at 450 nm using a microplate reader (Spectra-Max M3, Molecular Devices, USA). The cell viability is calculated according to the following formula: cell viability (%) = (A treatment - A blank)/ (A control - A blank) × 100%.

**Western blot**

The protein samples were collected from supernatants of OVV or OVV-CD19BiTE-infected HeLa-S3 cells. BCA assay was then conducted to measure the protein levels in these samples based on the provided directions. Equal protein amounts were separated via 10–15% SDS/PAGE and transferred onto PDF membranes that were probed with anti-FLAG (Abcam, ab205606). Blots were then probed with HRP-linked secondary antibodies (HuaAn Biotechnology) for 1 h.

**Binding assays**

To detect whether the secreted CD19BiTE could bind to the recombinant CD3ε protein (Cat#: CDD-H52W1, Acro) and CD19 protein (Cat#: CDD-H52H2, Acro), a FLAG-linked Elisa assay was performed. Briefly, 96-well plates were coated with CD3ε or CD19 protein at a concentration of 10 mg/ml. Then, supernatants of OVV-infected Hela-S3 cells were collected and added to the coated wells and incubated at 4 °C for 12 h. After that, the cell culture supernatant was removed, washed three times with 1 × TBS buffer, BiTE binding CD3ε and CD19 protein was determined by ELISA assays using anti-FLAG M2-HRP antibody (Cat#: A8592, Sigma–Aldrich). Binding assays were also performed with CD19+ tumor cells: K562/CD19, Raji, Farage, Pfeifer, Nalm-6 cells or CD3ε+ cells: Jurkat, CEM, Human T cells. Target cells (1 × 105) were incubated on ice for one hour with the OVV-infected supernatants. BiTE binding was determined by flow cytometry using APC anti-DYKDDDDK Tag antibody (Cat#: 637308, Biologend, USA).

**Enzyme-linked immunosorbent assay (ELISA)**

Human T cells were co-cultured with or without K562, K562/CD19, or Raji cells, respectively, in the presence of the OVV or OVV-CD19BiTE supernatants (100 μl) or blinatumomab (100 ng/ml) for 24 h. Then, supernatants were obtained from this co-culture system. Samples were centrifuged at 600 × g for 5 min at room temperature and the supernatants were collected. Human IFN-γ, TNF-α, and IL-2 in the supernatants were quantified using the ELISA MAXTM Standard Set (Cat#:30115, 430216, 431815, Biologend, USA) according to the manufacturing protocol.

**Quantitative polymerase chain reaction (qPCR)**

Frozen tumor samples were disrupted using a mortar and pestle under liquid nitrogen. RNA and DNA were isolated using approximately 25 μg of homogenized tissue with the DNA/RNA/protein kit (IBI Scientific). RNA samples were treated with the TURBO DNA-free kit (Thermo Fisher Scientific) to remove traces of genomic DNA. RNA (1 μg) was retro-transcribed with the High-Capacity cDNA Reverse Transcription kit (Thermo Fisher Scientific). Real-time analysis was performed in a LightCycler 480 Instrument II (Roche). To quantify the viral genomes and CD19BiTE transcripts in the tumor, 100 ng of DNA and 40 ng of cDNA in the presence of SYBR Green I Master (Roche) were used, respectively. PCR conditions were: 95 °C 10 min, 40 cycles of 95 °C 15 s, 60 °C 1 min and 72 °C 7 min. Viral genome primers were as follow: 5′- CGTGATCTACATCCGCCCCA-3′ and 5′- CTGGATCTACATCCGCCCCA-3′.
were either used for functional assays or cryopreserved. Cells were counted and fed daily until day 10, when they were used for functional assays or cryopreserved.

Preparation of peripheral blood mononuclear cells and T-cell isolation
All experiments were approved by the ethics committees of the Second Affiliated Hospital, College of Medicine, Zhejiang University. Every donor signed the informed consent. Blood samples were obtained from the healthy donors. And peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-density gradient centrifugation and resuspended in AIM-V medium (Gibco, Grand Island, New York, USA) with 10% FBS for incubation in a 37 °C, 5% CO2 humidified incubator. For preparing the T cells, PBMCs were isolated using T Cell Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany), then resuspended in AIM-V medium containing IL-2 (300 IU/ml), 5 ng/mL IL-7, and IL-15 (Prime Gene, Shanghai, China), as well as anti-CD3 and CD28 dynabeads (Gibco) with the ratio of 1:1 for activating T cells. For bioimaging studies, T cells were transduced with a lentivirus expressing GFP and the click beetle green luciferase (CBG) 24 h after activation. Cells were counted and fed daily until day 10, when they were used for functional assays or cryopreserved.

Cytotoxicity assays
To assess CD19BiTE-mediated cytotoxicity, CFSE-labeled target cells (Raji, K562/CD19, K562) were cultured with 5 × 10^5 T cells (E:T = 5) in 12-well plates. Mock, OV, or OV-CD19BiTE virus (1 MOI) supernatants (100 μl) or blinatumomab (100 ng/ml) were added. After 48 h of incubation, co-cultures were collected and stained with 7AAD (Thermo Fisher Scientific). Cells were analyzed by flow cytometry and the percentage of CFSE+/7AAD− was determined.

Xenograft mouse models
All animal experiments were approved by the Ethics Committee for Animal Experimentation from Zhejiang University. Raji or Raji-luc were subcutaneously or intravenously injected into female, 8-week-old, NOD/scid/IL2rg−/− (NSG) mice (bred in house). To evaluate T-cell trafficking to the tumor, mice bearing Raji subcutaneous tumor were treated intratumorally with PBS, OV, or OV-CD19BiTE (2 × 10^7 pfu/tumor). Twenty-four hours later, 1 × 10^7 preactivated CBG99-luciferase-expressing T cells were intravenously injected into treated mice. In another parallel experiment, CBG-luciferase-GFP expressing Raji cells (1 × 10^5 cells) were injected intravenously into NSG mice. Then PBS, OV, OV-CD19BiTE (2 × 10^7 pfu), or blinatumomab (0.25 mg/kg) were injected intraperitoneally with a single dose, and CBG99-luciferase-BFP expressing human T cells (1 × 10^7 cells) were injected intravenously. Mice were given an intraperitoneal injection of 15 mg/mL D-luciferin potassium salt solution (PerkinElmer) and imaged for indicated days using IVIS Lumina XRS Imaging System (PerkinElmer).
For in vivo antitumor efficacy studies, mice bearing Raji subcutaneous tumor were treated intratumorally with PBS or the indicated viruses (2 × 10^7 pfu/tumor) or blinatumomab (0.25 mg/kg) four times. Digital calipers were used to measure subcutaneous tumor diameter, with tumor volume being defined as: volume = length × width^2 × 0.5. The body weight and tumor sizes of all mice were regularly monitored, and mice were killed by
carbon dioxide suffocation if they exhibited acute weight loss or tumors ≥3000 mm³ in size. When tumors were no longer palpable, mice were considered to have achieved a CR. In another parallel experiment, CBG99-luciferase-expressing Raji cells were intravenously injected into NSG mice to establish disseminated xenograft mouse models of B-cell lymphoma. Then PBS, OVV, OVV-CD19BiTE (2 × 10⁷ pfu) or blinatumomab (0.25 mg/kg) were injected intraperitoneally three times. Every second day after OVV, OVV-CD19BiTE, or blinatumomab treatment, human T cells (1 × 10⁷ cells) were intravenously injected. Mice were given an intraperitoneal injection of 15 mg/mL D-luciferin potassium salt solution (PerkinElmer) and imaged for indicated days using IVIS Lumina XRMS Imaging System (PerkinElmer).
Flow cytometry analysis of T-cell differentiation

Raji lymphoma cells were implanted intradermally into the right flanks of NSG mice (5 × 10^6 cells). Mice bearing Raji subcutaneous tumors were treated intratumorally with PBS, OVV, OVV-CD19BiTE (2 × 10^7 pfu/tumor), or blinatumomab (0.25 mg/kg). Twenty-four hours later, 1 × 10^6 preactivated T cells were intravenously injected into treated mice. Tumors were harvested 3 days after the injection with forceps and surgical scissors and were weighed. They were then minced before incubation with Liberase (1.67 Wünsch U/mL) and DNase (0.2 mg/mL) in serum-free RPMI for 30 min at 37 °C. Cell suspensions were generated by mashing through a 70 μm filter and then washed with complete RPMI. For tumor-infiltrating T-cells analysis, single-cell suspensions were generated and processed for surface labeling with anti-CD3, anti-CD45RA, anti-CCR7, anti-CXCR3, and anti-CCR6 antibodies (Beckman). Live cells were distinguished from dead cells by using fixable dye eFluor506 (ebioscience). All flow data were acquired using either an LSRII flow cytometer (BD Biosciences). Data were analyzed with FlowJo software (Treestar).

Statistical analysis

SPSS 17.0 (IBM Corp., NY, U.S.A.) and GraphPad Prism (GraphPad Software, Inc.) were used for statistical testing. Continuous data are given as means ± standard deviation (SD), and were compared through unpaired two-tailed Student’s t-tests or two-way analyses of variance (ANOVA)s with Tukey’s multiple comparisons test. Kaplan–Meier curves were used to assess survival outcomes. P < 0.05 was the significance threshold.

RESULTS

Oncolytic vaccinia virus for expression of a BiTE targeting the CD19

We have recently reported the generation of an OVV armed with therapeutic genes such as miR-34a, Smac, and Beclin-1, which showed enhanced antitumor efficacy in hematologic malignancy [12, 13]. In the present study, we engineered a novel OVV to express a CD19-targeting BiTE under the control of the vaccinia virus major later promoter Pse/I (denoted as OVV-CD19BiTE). The CD19BiTE was constructed by joining two scFv specific for human CD3ε and human CD19 with a flexible linker (GS linker) (Fig. 1A). To evaluate whether CD19BiTE insertion affects the replication of the virus, B-lymphoma cell lines Raji, Pfeiffer, and Farage cell line, and K562/CD19 cell line was treated with an OVV that express GFP and OVV-CD19BiTE, respectively, and the replication kinetics of the viruses were determined by TCD50 mediated plaque-forming assays. There was no difference in the viral production of OVV and OVV-CD19BiTE (P > 0.05) (Fig. 1B). We next assessed the killing kinetics of the viruses in dose-response cytotoxicity assays. As shown in Fig. 1C, the oncolytic potential was not impaired by the insertion of BiTE transgenes. In summary, compared with control OVV, the replication and oncolytic ability of OVV-CD19BiTE were unimpaired by the transgene.

To evaluate the secretion of CD19BiTE by lymphoma cells upon viral infection and replication, cell-free supernatants of OVV-CD19BiTE-infected cells were analyzed SDS-PAGE and immunoblotting, which demonstrated BiTE expression and secretion (Fig. 1D). Furthermore, the secretion of the CD19BiTE was quantified from the supernatants of OVV-CD19BiTE infected cells by ELISA assay (Fig. S1). These results showed that the CD19BiTE was efficiently produced and released from OVV-CD19BiTE-infected cells.

Supernatants from OVV-CD19BiTE-infected cells induce activation and proliferation of human T cells

Next, the functionality of the secreted BiTEs by the OVV was assessed by flow cytometry-based binding assays using a fluorescent-labeled anti-FLAG antibody. For this study, a panel of lymphoma cell lines, K562/CD19 cell line, K562, and CD3+ Jurkat, CEM, and human T cells were used. CD19 antigen-binding specificity was demonstrated only in the supernatants of OVV-CD19BiTE-infected cells and they specifically bound to CD19+ lymphoma cells and CD19+ K562 cells, but not CD19+ K562 cells (Fig. 2A). The BiTEs also well bound to CD3+ Jurkat, CEM, and human T cells (Fig. 2B). To evaluate CD19BiTE-mediated T-cell effector functions, we investigated the ability of secreted BiTEs to activate PBMC-derived T cells by adding unstimulated human CD3+ cells to a culture of Raji cells. Supernatants from OVV-CD19BiTE-infected cells led to a significant increase in T-cell proliferation in a time-dependent manner, whereas the control OVV had no effect (Fig. 2C). Treatment with OVV-19BiTE supernatant or blinatumomab upregulated activation markers CD25, CD40L, and CD22.3 pg/mL, and 878.21 ± 43.2 vs 879.43 ± 34.2 pg/mL in the supernatant or blinatumomab. This result supports an existing BiTE-cytokine response of T-cell activation and cytotoxicity, levels of IL-2, IFNγ, and TNFα were detected in the co-culture system. As shown in Fig. 3A, the concentrations of IL-2, IFN-γ, and TNF-α were 423.4 ± 30.21 vs 417.2 ± 28.17 pg/mL, 312.32 ± 33.43 vs 289.7 ± 22.3 pg/mL, and 878.21 ± 43.2 vs 879.43 ± 34.2 pg/mL in the supernatant obtained from Raji and K562/CD19 group, respectively, all of which were significantly higher than that of the control groups. Similar results were also observed in the co-culture in the presence of blinatumomab.

Characterization and superior cytotoxicity of OVV-CD19BiTE in vitro

We next assessed whether the secreted CD19BiTE would kill B-lymphoma cells and whether the cytotoxicity by this CD19BiTE is antigen-specific. Cytotoxicity of human T cells in the presence of supernatants from OVV-infected cells and OVV-CD19BiTE, or blinatumomab, respectively, were measured in three different cancer cell lines. The secreted CD19BiTE and blinatumomab elicited strong cytotoxicity in Raji and K562/CD19 cells, but not in K562 cells, indicating that the secreted CD19BiTE-mediated cytotoxicity was dependent on CD19 expression (Fig. 3B). Recent studies demonstrated that BiTEs could also mediate a bystander killing of adjacent tumor cells [17]. To determine whether CD19BiTE mediate the bystander effect, CFSE-stained K562 cells or K562/CD19 were co-cultured with human T cells. Then the supernatants obtained from OVV or OVV-CD19BiTE-infected cells or blinatumomab were added to this co-culture system. The cell death in CFSE-labeled target cells was assessed by flow cytometry. As shown in Fig. 3C, we observed obvious cytotoxicity of K562 cells only when co-cultured together with OVV-CD19BiTE supernatants or blinatumomab. This result supports an existing BiTE-dependent T-cell-induced bystander lysis of CD19-negative cells. To investigate the enhanced antilymphoma efficacy mediated by
The percentage of cytotoxicity of target cells (CFSE at an MOI of 2 or control OVV (MOI stained by CFSE, in the presence of blinatumomab, OVV-CD19BiTE K562/CD19 cells, OVV-CD19BiTE treatment elicited significantly increased cell death (Fig. 3D), demonstrated superior in vitro CD19 cytotoxicity.

It is known that BiTEs are uniquely designed both to redirect and to a tumor and stimulating T-cells proliferation. OVV-CD19BiTE are capable of recruiting an immune response which was observed in 4 days (Fig. 4C, D). Meanwhile, the treatment of both OVV-CD19BiTE and blinatumomab group compared with OVV, the treated mice. The peak levels of T-cell expansion were higher in OVV-CD19BiTE treated mice but not of the control groups (Fig. 4A, B), suggesting that infused T cells were effectively recruited into tumor sites.

OVV-CD19BiTE are capable of recruiting an immune response to a tumor and stimulating T-cells proliferation. It is known that BiTEs are uniquely designed both to redirect and recruit T cells to tumor tissues [23–25]. In this study, T lymphocytes that infiltrated into tumor sites were investigated. For this purpose, Raji cells were engrafted in the subcutaneous flank of NSG mice and then PBS, OVV, or OVV-CD19BiTE were intratumorally injected, respectively. Twenty-four hours later, luciferase-expressing human T cells were given by intravenous injection (IV). Bioluminescence (BLI) images showed that there was straightforward recruitment of T lymphocytes in tumors of OVV-CD19BiTE treated mice but not of the control groups (Fig. 4A, B), suggesting that infused T cells were effectively recruited to the tumor sites.

To investigate T-cell proliferation and its relationship with antitumor activity in vivo, mice bearing carcinomatosis established by vein injection of Raji cells were treated with a single dose of OVV, OVV-CD19BiTE, or blinatumomab, respectively, and then human T cells that expressed CBG99-luciferase-BFP were also infused into the treated mice. The peak levels of T-cell expansion were higher in both OVV-CD19BiTE and blinatumomab group compared with OVV, which was observed in 4 days (Fig. 4C, D). Meanwhile, the treatment with either OVV-CD19BiTE or blinatumomab was able to significantly inhibit tumors developed by Raji cells (Fig. 4E).

OVV-CD19BiTE confers superior antilymphoma activity compared with blinatumomab in vivo

After demonstrating the efficacy of OVV-CD19BiTE in vitro, we moved forward to determine the antilymphoma activity of this novel OVV product in vivo using two distinct models in NSG mice. In the first model, Raji cells were injected subcutaneously leading to xenografts. The mice bearing established tumors (tumor volume reached 80–100 mm³) received intratumoral (IT) injection of OVV, OVV-CD19BiTE, or intraperitoneal (IP) injection of blinatumomab, respectively. PBS was used as a negative control. One day later, human T cells were IV administered to treated mice. As shown in Fig. 5A, OVV-CD19BiTE-treated tumors were substantially delayed in their growth. At 33 days after initiation of the treatment, all mice were euthanized and tumors were excised, and then tumor volumes were calculated. Xenografts of mice treated with OVV-CD19BiTE only have an average tumor volume of 64.3 mm³. In contrast, mean tumor volumes were 3200.3, 967.2, and 509.1 mm³ in PBS-, OVV-, and blinatumomab-treated groups, respectively (Fig. 5B). Importantly, complete elimination of tumors was observed in 3/10 mice treated with OVV-CD19BiTE, and 2/10 mice treated with blinatumomab, respectively.

To understand why OVV-CD19BiTE is much more effective than OVV or blinatumomab in generating antitumor effects, we performed another parallel animal experiment and investigated the difference in number and phenotype of T cells within tumors across the treatment groups. After establishing Raji-xenograft, mice were randomized into treatment groups that received intratumoral administration of PBS, OVV, OVV-CD19BiTE, or intraperitoneal...
administration of blinatumomab, respectively, and then human PBMC were also administrated by intravenous infusion. Three days later, the tumors were harvested to obtain cell suspensions. Tumors treated with OVV-CD19BiTE and blinatumomab showed an increased percentage of infiltrating T cells that included various phenotypes such as CD4, CD8, naïve CD8 (CD8\(^+\) CD45RA\(^+\) CCR7\(^+\)), central memory CD8 (CD8\(^+\) CD45RA\(^−\) CCR7\(^+\)), effector memory CD8 (CD8\(^+\) CD45RA\(^−\) CCR7\(^−\)), effector CD8 (CD8\(^+\) CD45RA\(^+\) CCR7\(^+\)), Th1 (CD4\(^+\) CXC3\(^+\) CCR6\(^+\)), and Th2 (CD4\(^+\) CXC3\(^−\) CCR6\(^−\)) cells when compared with OVV or PBS. Importantly, OVV-CD19BiTE contributed to a more significantly increased percentage of CD3, CD8, and naïve CD8 T cells in contrast to blinatumomab (Fig. 5C and Fig. S2).

To evaluate the speciality of the biodistribution of OVV-CD19BiTE and the expression of CD19BiTE after intratumoral injection, an independent animal study was conducted. Ten mice bearing xenograft subcutaneous Raji tumors were intratumorally injected with PBS, OVV, or OVV-CD19BiTE (2 \times 10^7 pfu/tumor). 24 h later, mice received an intravenous injection of preactivated T cells expressing luciferase gene (T-luc cells, 1 \times 10^7 cells/mouse). Luciferase activity was analyzed by bioluminescence imaging (IVIS) until day 12. Mean values ± SD with 4 animals per group are shown. **P < 0.01; ***P < 0.001, OVV-CD19BiTE significant by one-way ANOVA test with post-hoc analysis compared to PBS and OVV groups. C-F CBR-luciferase-GFP expressing Raji cells were injected intravenously into NSG mice on Day –10, then injected i.p. with a single dose of PBS, OVV, OVV-CD19BiTE (2 \times 10^7 pfu) or blinatumomab (0.25 mg/kg) and injected intravenously with CBB99-luciferase-BFP expressing human T cells on Day 0. Images of respective mice about T-cell stimulation (C) and tumor progression (E) were shown. Luciferase activity of T cells (D) and Raji cells (F) was analyzed by bioluminescence imaging. A representative result of triplicates is shown. **P < 0.01, using one-way ANOVA test with post-hoc analysis.

Fig. 4 OVV-CD19BiTE induces accumulation and increased persistence of tumor-infiltrating T cells in vivo. A NSG mice bearing subcutaneous Raji tumors were intratumorally injected with PBS, OVV, or OVV-CD19BiTE (2 \times 10^7 pfu/tumor). 24 h later, mice received an intravenous injection of preactivated T cells expressing luciferase gene (T-luc cells, 1 \times 10^7 cells/mouse). Images of respective mice were shown. B Luciferase activity was analyzed by bioluminescence imaging (IVIS) until day 12. Mean values ± SD with 4 animals per group are shown. **P < 0.01; ***P < 0.001, OVV-CD19BiTE significant by one-way ANOVA test with post-hoc analysis compared to PBS and OVV groups. C-F CBR-luciferase-GFP expressing Raji cells were injected intravenously into NSG mice on Day –10, then injected i.p. with a single dose of PBS, OVV, OVV-CD19BiTE (2 \times 10^7 pfu) or blinatumomab (0.25 mg/kg) and injected intravenously with CBB99-luciferase-BFP expressing human T cells on Day 0. Images of respective mice about T-cell stimulation (C) and tumor progression (E) were shown. Luciferase activity of T cells (D) and Raji cells (F) was analyzed by bioluminescence imaging. A representative result of triplicates is shown. **P < 0.01, using one-way ANOVA test with post-hoc analysis.
BLI imaging (Fig. 5F). Moreover, OVV-CD19BiTE was most effective for controlling Raji tumor cell growth, and three of five mice treated with OVV-CD19BiTE remained tumor-free for up to 162 days post-treatment, which resulted in significantly improved overall survival compared to OVV or even blinatumomab treatment (Fig. 5F, G).

**DISCUSSION**

Current developments in immunotherapy using BiTEs show remarkable efficacy in certain subgroups of cancer patients. Blinatumomab is an anti-CD19BiTE with excellent cell-binding capacities. It was approved for use in patients with R/R B-cell
Fig. 5 OVV-CD19BiTE shows improved antitumor efficacy in vivo. A NSG mice bearing subcutaneous Raji tumors were treated with PBS, OVV, OVV-CD19BiTE (2 × 10^7 pfu/tumor, I.T.) or blinatumomab (0.25 mg/kg, I.P.) every 3 days for four times. 24 h after virus treatment, animals were infused with preactivated T cells (1 × 10^7 cells, I.V.) for four times. The mean tumor growth ±SD is shown (n = 10). B At the end of the experiment about panel A (Day 33), tumor volumes were compared among groups. C In another parallel experiment, NSG mice bearing subcutaneous Raji tumors were treated with PBS, OVV, OVV-CD19BiTE (2 × 10^7 pfu/tumor, I.T.) or blinatumomab (0.25 mg/kg, I.P.) On day 3 after virus treatment, T cell suspension was prepared. Percentage of CD3, CD8, CD4, naive CD8, and Th1 cells were analyzed by flow cytometry. **p < 0.01; ***p < 0.001; ****p < 0.0001; ns no significance, using one-way ANOVA test with post-hoc analysis. D On day 3 and 7 after virus infection, the DNA content of CD19BiTE in heart, liver, spleen, lung, kidney, and tumor was detected by qPCR. E The mRNA level of CD19BiTE of tumors was detected by qRT-PCR. F NSG mice model of systemic tumorigenesis of Raji-luc cells were intraperitoneally injected with PBS, OVV, OVV-CD19BiTE (1 × 10^7 pfu/tumor) or blinatumomab (0.25 mg/kg, I.P.) every three days for four times. 24 h after every virus treatment, animals were treated with preactivated T cells (1 × 10^7 cells, I.V.) for four times. Luciferase activity of Raji-luc was analyzed by bioluminescence imaging (IVIS) at indicated day until day 162 (n = 5). G Kaplan–Meier analysis was performed to assess the statistical difference between different treatment groups. **p < 0.01, using one-way ANOVA test with post-hoc analysis.

In this study, significant increased infiltration and expansion of T cells were found in subcutaneous tumors treated with the OVV-CD19BiTE after intravenous T-cell infusion. Another noteworthy finding in our in vivo experiments was that OVV-CD19BiTE-treated tumors harbored high numbers of T cells, with 55.9% CD8+ tumor-infiltrating lymphocytes. Treatment with OVV-CD19BiTE also led to significantly increased naive CD8 T subpopulation within tumors compared to OVV and blinatumomab treatment. This difference may contribute to the superior antitumor activity of OVV-CD19BiTE because it was demonstrated that naïve and memory T-cells surpass effector T cells in induction of potent antitumor responses for adoptive cell therapy [28]. However, to elucidate the interaction between the OVV-CD19BiTE and the immune cells within TME, further studies using an immunocompetent mouse model, but not NSG mouse model, are required.

Systemic delivery is a major goal in the field of virotherapy, which is the preferred route of administration in many clinical situations for the oncolytic virus to maximize the delivery of the virus to metastatic cancers [29]. Several preclinical and clinical trials have revealed the remission of disseminated cancer after systemic oncolytic virotherapy [30–33]. In this study, a mouse model with disseminated B-cell tumors was established by intravenous injection of Raji cells. Treatment with OVV-CD19BiTE delivered intraperitoneally significantly suppressed the growth of Raji tumors compared with control OVV and blinatumomab, and led to a substantial response, surprisingly, three of five mice (60%) given OVV-CD19BiTE achieved long-term tumor remissions without relapse and had very long survival.

In summary, our findings provide preclinical evidence for the therapeutic potential of OVV-CD19BiTE, and show that OVV-CD19BiTE activated human T cells, induced recruitment of T cells, and significantly increased naive and central memory T subpopulations within TME, thereby enhancing antilymphoma activity in preclinical models. Thus, this novel OVV could circumvent limitations in current BiTE therapy and may translate into meaningful therapeutic effects in the treatment of B-cell lymphomas.

DEKLARATIONS

The animal experiments were approved by the Institutional Animal Care and Use Committee, Zhejiang University. The studies involving human participants were reviewed and approved by an independent Ethics Committee of The Second Affiliated Hospital, College of Medicine, Zhejiang University. The participants provided their written informed consent to participate in this study.

DATA AVAILABILITY

The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

REFERENCES

1. Locke FL, Go WY, Neelapu SS. Development and use of the anti-CD19 chimeric antigen receptor T-cell therapy axicabtagene ciloleucel in large B-cell lymphoma: a review. JAMA Oncol. 2020;6:281–90.
2. Frigault MJ, Maus MV. State of the art in CAR T cell therapy for CD19+ B cell malignancies. J Clin Invest. 2020;130:1586–94.

3. Deising W, Raum T, Kuper F, Baueerle PA, Munz M. Impact of diverse immune evasion mechanisms of cancer cells on T cells engaged by EpCAM/CD3-bispecific antibody construct AMG 110. PLos ONE. 2015;10:e0141669.

4. Labrijn AF, Jannata ML, Reichert JM, Parren P. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18:585–608.

5. Kantarjian H, Stein A, Gobguet N, Fielding AK, Schuh AC, Ribera JM, et al. Bli-natumbomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376:836–47.

6. Viardot A, Locatelli F, Stiegmaier J, Zaman F, Jabbour E. Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies. Ann Hematol. 2020;99:2215–29.

7. Takos M, Heo J, Lee HC, Tak WY, Chao Y, Paik SW, et al. Vaccinia-based immunotherapeutics to overcome tumor heterogeneity. Expert Rev Vaccines. 2019;18:663–674.

8. Freedman JD, Duffy MR, Lei-Rossmann J, Muntzer A, Scott EM, Hagel J, et al. An antibody construct AMG 110. PLoS ONE. 2015;10:e0141669.

9. Lawler SE, Speranza MC, Cho CF, Chiocca EA. Oncolytic viruses in cancer treatment: a review. JAMA Oncol. 2017;3:841–9.

10. Dao T, Pankov D, Scott A, Korontsvit T, Zakhaleva V, Xu Y, et al. Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. Nat Biotechnol. 2015;33:1079–86.

11. Zhang B, Wang X, Cheng P. Remodeling of tumor immune microenvironment by oncolytic vaccinia virus armed with Beclin-1, an autophagic Gene in leukemia and myeloma. Biomed Pharmacother. 2020;125:110300.

12. Lei W, Wang S, Xu N, Chen Y, Wu G, Zhang A, et al. Enhancing therapeutic efficacy of oncolytic vaccinia virus armed with Beclin-1, an autophagic Gene in leukemia and myeloma. Biomed Pharmacother. 2020;125:110300.

13. Lei W, Wang S, Yang C, Huang X, Chen Z, He W, et al. Combined expression of miR-34a and Smac mediated by oncolytic vaccinia virus synergistically promote anti-tumor effects in Multiple Myeloma. Sci Rep. 20166;31274.

14. Qian W, Lu J, Tong Y, Yan S, Yang C, Yang M, et al. Enhanced antitumor activity by a selective conditionally replicating adenovirus combining with MDA-7/interleukin-24 for B-lymphoblastic leukemia via induction of apoptosis. Leukemia. 2008;22:361–9.

15. Pelin A, Boulton S, Tamming LA, Bell JC, Singaravelu R. Engineering vaccinia virus as an immunotherapeutic battleship to overcome tumor heterogeneity. Expert Opin Biol Ther. 2020;20:10183–97.

16. Yu F, Wang X, Guo ZS, Bartlett DL, Gottschalk SM, Song XT. T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy. Mol Ther. 2014;22:102–11.

17. Fajardo CA, Guedan S, Rojas LA, Moreno R, Arias-Badía M, de Sotoa J, et al. Oncolytic adenoviral delivery of an EGFR-targeting T-cell engager improves antitumor efficacy. Cancer Res. 2017;77:2052–63.

18. Freedman JD, Duffy MR, Lei-Rossmann J, Muntzer A, Scott EM, Hagel J, et al. An oncolytic virus expressing a T-cell engager simultaneously targets cancer and immunosuppressive stromal cells. Cancer Res. 2018;78:6852–65.

19. Guo ZS, Lotze MT, Zhu Z, Storkus WJ, Song XT. Bi- and tri-specific T cell engager-armed oncolytic viruses: next-generation cancer immunotherapy. BioMedicines. 2020;8:204.

20. Albelda SM, Thorne SH. Giving oncolytic vaccinia virus more BiTE. Mol Ther. 2014;22:6–8.

21. Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, et al. Intravenously delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature. 2011;477:99–102.

22. Moehler M, Heo J, Lee HC, Tak WY, Chao Y, Paik SW, et al. Vaccinia-based oncolytic immunotherapy Paxistimogene Davaserep in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase Ib trial (TRAVERSE). Oncoimmunology. 2019;8:1615817.

23. Heidbuechel JPW, Engelard CE. Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies. J Hematol Oncol. 2021;14:63.

24. Fu M, He Q, Guo Z, Zhou X, Li H, Zhao L, et al. Therapeutic bispecific T-cell engager antibody targeting the transferrin receptor. Front Immunol. 2019;10:1396.

25. Lejeune M, Kose MC, Duray E, Eisele H, Beguin Y, Caers J. Bispecific, T-cell-recruiting antibodies in B-cell malignancies. Front Immunol. 2020;11:762.

26. Speck T, Heidbuechel JPW, Vennalde R, Jaeger D, von Kalle C, Bell CR, et al. Targeted BITE expression by an oncolytic virus augments therapeutic efficacy against solid tumors. Clin Cancer Res. 2018;24:2128–37.